Larvol Cliniclarvol.hashnode.devยทAug 8, 2024Trial: Ponatinib vs Imatinib in Ph+ ALLImportance: In newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), disease progression due to acquired resistance to first- or second-generation BCR::ABL1 tyrosine kinase inhibitors is common. Ponatinib inhibits...CancerAdd a thoughtful commentNo comments yetBe the first to start the conversation.
